{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:10:25Z","timestamp":1790079025940,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ijantimicag.2018.12.001","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T18:30:41Z","timestamp":1544293841000},"page":"416-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Impact of a multimodal strategy combining a new standard of care and restriction of carbapenems, fluoroquinolones and cephalosporins on antibiotic consumption and resistance of Pseudomonas aeruginosa in a French intensive care unit"],"prefix":"10.1016","volume":"53","author":[{"given":"Salam","family":"Abbara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lia","family":"Pitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Jochmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyann","family":"Hodjat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Cherrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Monchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Vinsonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6272-4707","authenticated-orcid":false,"given":"Sylvain","family":"Diamantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0001","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2110-5820-1-47","article-title":"The rising problem of antimicrobial resistance in the intensive care unit","volume":"1","author":"Brusselaers","year":"2011","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0002","doi-asserted-by":"crossref","first-page":"a1438","DOI":"10.1136\/bmj.a1438","article-title":"Meeting the challenge of antibiotic resistance","volume":"337","author":"Cars","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0003","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1128\/AAC.01823-12","article-title":"Emergence of imipenem-resistant Gram-negative bacilli in intestinal flora of intensive care patients","volume":"57","author":"Armand-Lef\u00e8vre","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0004","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00134-013-2914-z","article-title":"Risk factors for carbapenem-resistant Gram-negative bacteremia in intensive care unit patients","volume":"39","author":"Routsi","year":"2013","journal-title":"Intensive Care Med"},{"issue":"Suppl 4","key":"10.1016\/j.ijantimicag.2018.12.001_bib0005","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/382690","article-title":"'Collateral damage' from cephalosporin or quinolone antibiotic therapy","volume":"38","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"Suppl 4","key":"10.1016\/j.ijantimicag.2018.12.001_bib0006","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1086\/500664","article-title":"Hospital-based strategies for combating resistance","volume":"42","author":"Owens","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0007","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/CCM.0b013e31828e9863","article-title":"Impact of regular collaboration between infectious diseases and critical care practitioners on antimicrobial utilization and patient outcome","volume":"41","author":"Rimawi","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5492\/wjccm.v4.i1.13","article-title":"Antibiotic stewardship programmes in intensive care units: why, how, and where are they leading us","volume":"4","author":"Zhang","year":"2015","journal-title":"World J Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0009","article-title":"Evaluation of the short-term effects of antimicrobial stewardship in the intensive care unit at a tertiary hospital in China","volume":"9","author":"Hou","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.epidem.2012.12.001","article-title":"Linking antimicrobial prescribing to antimicrobial resistance in the ICU: before and after an antimicrobial stewardship program","volume":"4","author":"Hurford","year":"2012","journal-title":"Epidemics"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0011","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s15010-013-0531-y","article-title":"Antibiotic stewardship in Germany: a cross-sectional questionnaire survey of 355 intensive care units","volume":"42","author":"Maechler","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0012","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-015-3853-7","article-title":"Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric)","volume":"41","author":"Bretonni\u00e8re","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0013","first-page":"649","article-title":"Elaboration of a consensual definition of de-escalation allowing a ranking of \u03b2-lactams","volume":"21","author":"Weiss","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0014","article-title":"EUCAST guideline for the detection of resistance mechanisms and specific resistances of clinical and\/or epidemiological importance. Version 2.0, July 2017","year":"2017","journal-title":"EUCAST"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0015","first-page":"38","article-title":"Tableaux des concentrations critiques pour l'interpretation des CMI et des diam\u00e8tres critiques des zones d'inhibition","year":"2018","journal-title":"CASFM\/EUCAST"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0016","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF01133616","article-title":"Medical record keeping in France: the French PMSI system and anaesthesiology","volume":"9","author":"Ranch\u00e8re","year":"1992","journal-title":"Int J Clin Monit Comput"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0017","first-page":"882","article-title":"Trimethoprim\/sulfamethoxazole versus vancomycin in the treatment of healthcare\/ventilator-associated MRSA pneumonia: a case\u2013control study","volume":"72","author":"Eliakim-Raz","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0018","article-title":"Impact of a multimodal antimicrobial stewardship program on Pseudomonas aeruginosa susceptibility and antimicrobial use in the intensive care unit setting","volume":"2011","author":"Slain","year":"2011","journal-title":"Crit Care Res Pract"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0019","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ijantimicag.2007.05.012","article-title":"Impact of an antibiotic restriction policy on the antibiotic resistance patterns of Gram-negative microorganisms in an intensive care unit in Greece","volume":"30","author":"Ntagiopoulos","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0020","first-page":"503","article-title":"Carbapenem restriction and its effect on bacterial resistance in an intensive care unit of a teaching hospital","volume":"12","author":"Sistanizad","year":"2013","journal-title":"Iran J Pharm Res"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jhin.2004.07.016","article-title":"Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit","volume":"59","author":"Aubert","year":"2005","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0022","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.280.14.1233","article-title":"Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella","volume":"280","author":"Rahal","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0023","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1164\/ajrccm.162.3.9905050","article-title":"Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria","volume":"162","author":"Gruson","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0024","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s10156-006-0452-0","article-title":"Impact of ceftazidime restriction on Gram-negative bacterial resistance in an intensive care unit","volume":"12","author":"Brahmi","year":"2006","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0025","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1469-0691.2007.01681.x","article-title":"Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium","volume":"13","author":"Mesaros","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0026","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1186\/cc10026","article-title":"Pseudomonas aeruginosa acquisition on an intensive care unit: relationship between antibiotic selective pressure and patients\u2019 environment","volume":"15","author":"Boyer","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0027","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/381550","article-title":"Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity","volume":"38","author":"Paramythiotou","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0028","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1086\/523280","article-title":"Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals","volume":"28","author":"Rogues","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0029","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhin.2006.04.015","article-title":"Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature","volume":"64","author":"Falagas","year":"2006","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.ijantimicag.2018.12.001_bib0030","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/jac\/dkt403","article-title":"Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime","volume":"69","author":"Grohs","year":"2014","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T06:37:07Z","timestamp":1565764627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918303613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0924857918303613"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.12.001","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of a multimodal strategy combining a new standard of care and restriction of carbapenems, fluoroquinolones and cephalosporins on antibiotic consumption and resistance of Pseudomonas aeruginosa in a French intensive care unit","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}